eprintid: 1499899
rev_number: 29
eprint_status: archive
userid: 608
dir: disk0/01/49/98/99
datestamp: 2016-06-19 00:45:57
lastmod: 2021-12-13 02:36:17
status_changed: 2016-09-05 15:45:21
type: article
metadata_visibility: show
creators_name: Smyth, EC
creators_name: Fassan, M
creators_name: Cunningham, D
creators_name: Allum, WH
creators_name: Okines, AF
creators_name: Lampis, A
creators_name: Hahne, JC
creators_name: Rugge, M
creators_name: Peckitt, C
creators_name: Nankivell, M
creators_name: Langley, R
creators_name: Ghidini, M
creators_name: Braconi, C
creators_name: Wotherspoon, A
creators_name: Grabsch, HI
creators_name: Valeri, N
title: Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial
ispublished: pub
divisions: UCL
divisions: B02
divisions: D65
divisions: J38
note: Copyright © 2016 by American Society of Clinical Oncology. Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
abstract: PURPOSE: The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for patients with resectable esophagogastric cancer. However, identification of patients at risk for relapse remains challenging. We evaluated whether pathologic response and lymph node status after neoadjuvant chemotherapy are prognostic in patients treated in the MAGIC trial. MATERIALS AND METHODS: Pathologic regression was assessed in resection specimens by two independent pathologists using the Mandard tumor regression grading system (TRG). Differences in overall survival (OS) according to TRG were assessed using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate analyses using the Cox proportional hazards method established the relationships among TRG, clinical-pathologic variables, and OS. RESULTS: Three hundred thirty resection specimens were analyzed. In chemotherapy-treated patients with a TRG of 1 or 2, median OS was not reached, whereas for patients with a TRG of 3, 4, or 5, median OS was 20.47 months. On univariate analysis, high TRG and lymph node metastases were negatively related to survival (Mandard TRG 3, 4, or 5: hazard ratio [HR], 1.94; 95% CI, 1.11 to 3.39; P = .0209; lymph node metastases: HR, 3.63; 95% CI, 1.88 to 7.0; P < .001). On multivariate analysis, only lymph node status was independently predictive of OS (HR, 3.36; 95% CI, 1.70 to 6.63; P < .001). CONCLUSION: Lymph node metastases and not pathologic response to chemotherapy was the only independent predictor of survival after chemotherapy plus resection in the MAGIC trial. Prospective evaluation of whether omitting postoperative chemotherapy and/or switching to a noncross-resistant regimen in patients with lymph node-positive disease whose tumor did not respond to preoperative epirubicin, cisplatin, and fluorouracil may be appropriate.
date: 2016-08-10
date_type: published
official_url: http://dx.doi.org/10.1200/JCO.2015.65.7692
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
article_type_text: Journal Article
verified: verified_manual
elements_id: 1135976
doi: 10.1200/JCO.2015.65.7692
pii: JCO.2015.65.7692
lyricists_name: Langley, Ruth
lyricists_name: Nankivell, Matthew
lyricists_id: RELAN40
lyricists_id: MNANK23
full_text_status: public
publication: Journal of Clinical Oncology
volume: 34
number: 23
pagerange: 2721-2727
issn: 1527-7755
citation:        Smyth, EC;    Fassan, M;    Cunningham, D;    Allum, WH;    Okines, AF;    Lampis, A;    Hahne, JC;                                     ... Valeri, N; + view all <#>        Smyth, EC;  Fassan, M;  Cunningham, D;  Allum, WH;  Okines, AF;  Lampis, A;  Hahne, JC;  Rugge, M;  Peckitt, C;  Nankivell, M;  Langley, R;  Ghidini, M;  Braconi, C;  Wotherspoon, A;  Grabsch, HI;  Valeri, N;   - view fewer <#>    (2016)    Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.                   Journal of Clinical Oncology , 34  (23)   pp. 2721-2727.    10.1200/JCO.2015.65.7692 <https://doi.org/10.1200/JCO.2015.65.7692>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/1499899/1/Smyth%20et%20al%20Effect%20of%20Pathologic%20Tumor%20Response%20and%20Nodal%20Status%20on%20Survival%20in%20the%20Medical%20Research%20Council%20Adjuvant%20Gastric%20Infusional%20Chemotherapy%20Trial%20VoR.pdf